Result for
Tag: treatment
December 8, 2020
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
In a US household-randomized, double-blind, placebo-controlled trial among PCR-negative close contacts of persons with confirmed SARS-CoV-2 infection (n=689), no difference in SARS-CoV-2 acquisition by day 14 was observed between those receiving hydroxychloroquine post-exposure prophylaxis or placebo (HR = 1.10, 95% CI = 0.73-1.66). More participants in the hydroxychloroquine group experienced adverse events, including gastrointestinal symptoms…
December 4, 2020
Metformin and Risk of Mortality in Patients Hospitalised with COVID-19: A Retrospective Cohort Analysis
Metformin was associated with significantly reduced mortality among women with obesity or type 2 diabetes who were hospitalized with COVID-19, according to a retrospective cohort analysis using de-identified claims data (HR=0.79, 95%CI 0.65–0.95). Metformin use was not associated with a reduction in mortality among men in the study. Bramante et al. (Dec 3, 2020). Metformin…
COVID-19 Investigational Treatments in Use among Hospitalized Patients Identified through the U.S. Coronavirus Disease 2019 -Associated Hospitalization Surveillance Network, March 1–June 30, 2020
Data analyzed from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) indicate that among hospitalized individuals in the US with COVID-19 and with available data from March 1–June 30, 43% of received at least one COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir…
December 2, 2020
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
In a randomized trial of 11,330 adult inpatients with COVID-19 from 30 countries, with 2750 assigned to remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug, all trial drugs had little or no effect on overall mortality, initiation of ventilation,…
November 25, 2020
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19
An open-label, cluster-randomized trial of healthy contacts of patients with PCR–confirmed SARS-CoV-2 infection in Spain found that hydroxychloroquine did not prevent infection or symptomatic COVID-19 in these individuals. The incidence of PCR-confirmed, symptomatic COVID-19 was similar between those who received hydroxychloroquine and those who received usual care (5.7% and 6.2%, respectively; RR = 0.86). Hydroxychloroquine…
Retrospective Cohort Study of Admission Timing and Mortality Following COVID-19 Infection in England
A retrospective cohort study of 6,068 COVID-19 patients in England found that each additional day between symptom onset and hospital admission was associated with a 1% increase in the risk of mortality. Healthcare workers, obese people, and Black, Asian, and other ethnic minorities were more likely to experience later hospital admission, which the authors suggest…
November 24, 2020
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
A randomized placebo-controlled trial of convalescent plasma (CP) infusion for patients with severe COVID-19 (n=228) found no significant difference between the treatment and placebo groups in the improvement in clinical status measured at 30 days using an ordinal scale (OR=0.83, 95%CI 0.52 – 1.35). Overall mortality was 11% in the CP group and 11.4% in…
November 20, 2020
Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial
In a randomized, multicenter, open-label, parallel-arm, Phase 3 trial of adults in India with non-severe COVID-19 (including asymptomatic patients), those who received the antiviral drug favipavir within seven days of symptoms onset had faster clinical recovery compared to placebo. Median time to clinical cure was 3 days (95%CI: 3-4 days) in those who received oral…
November 18, 2020
Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19 A Multicenter Double-Blind Randomized Controlled Trial
[Preprint, not peer-reviewed] Administration of a single oral dose of vitamin D3 supplementation to hospitalized patients with severe COVID-19 did not show significant effect in reducing hospital length of stay (7 days vs. 7 days, p=0.4), mortality (7% vs. 5%, p=0.6), ICU admission (16% vs. 21%; p=0.3), or mechanical ventilation requirement (7% vs 14%; p=0.1)…
November 16, 2020
Safety and Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
A phase 2 randomized, double-blind, placebo-controlled trial of inhaled nebulized interferon beta-1a (SNG001) for patients hospitalized with COVID-19 (n=101) found that patients who received the study drug had greater odds of improvement on the WHO ordinal scale for clinical improvement (OSCI) (OR = 2.32) on day 15 or 16 and were more likely to recover…
Previous page Next page